D-0038-2024 Class II Terminated

Recalled by Zydus Pharmaceuticals (USA) Inc — Pennington, NJ

FDA drug recall D-0038-2024 was initiated by Zydus Pharmaceuticals (USA) Inc on Sep 21, 2023 and is designated Class II. Reason for recall: Failed Dissolution Specifications The recall status is terminated (terminated Aug 6, 2025). Affected quantity: 7,248 bottles.

Recall details

Product Type
Drugs
Report Date
Oct 11, 2023
Initiation Date
Sep 21, 2023
Termination Date
Aug 6, 2025
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
7,248 bottles

Product description

Oxybutynin Chloride Extended-Release Tablets USP 10 mg, a) 100 tablets (NDC 68382-256-01) and b) 500 tablets (NDC 68382-256-05) bottles, Rx Only, Manufactured by: Cadila Healthcare Ltd., Ahmedabad, India, Distributed by: Zydus Pharmaceuticals (USA) Inc., Pennington, NJ 08534

Reason for recall

Failed Dissolution Specifications

Distribution pattern

Nationwide in the USA.

Code information

Lot#: M300652 and M300651, exp. Dec 2024

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0038-2024
openFDA file date
Nov 10, 2026
Loaded by RegDataLab
Nov 11, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0038-2024. Report a data issue: hello@regdatalab.com.